Literature DB >> 31862960

Do persons with chronic myeloid leukaemia have normal or near normal survival?

Tomas Radivoyevitch1, Davis Weaver2, Brian Hobbs1, Jaroslaw P Maciejewski1, Rudiger Hehlmann3, Qian Jiang4, Andreas Hochhaus5, Robert Peter Gale6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31862960     DOI： 10.1038/s41375-019-0699-y

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

Review 1.  Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.

Authors:  Michele Baccarani; Robert Peter Gale
Journal:  Leukemia       Date:  2021-05-17       Impact factor: 11.528

2.  Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA).

Authors:  Massimo Breccia; Simone Celant; Pier Paolo Olimpieri; Odoardo M Olimpieri; Fabrizio Pane; Alessandra Iurlo; Alessia Cirilli; Antonietta Colatrella; Lucia Gozzo; Sara Pugliese; Valentina Summa; Paolo Foggi; Paolo Corradini; Pierluigi Russo
Journal:  Ann Hematol       Date:  2021-01-07       Impact factor: 3.673

3.  Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.

Authors:  Kelly L Schoenbeck; Ehab Atallah; Li Lin; Kevin P Weinfurt; Jorge Cortes; Michael W N Deininger; Vamsi Kota; Richard A Larson; Michael J Mauro; Vivian G Oehler; Javier Pinilla-Ibarz; Jerald P Radich; Charles A Schiffer; Neil P Shah; Richard T Silver; James E Thompson; Kathryn E Flynn
Journal:  J Natl Cancer Inst       Date:  2022-01-11       Impact factor: 11.816

4.  Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees.

Authors:  Eric J Chow; David R Doody; Jennifer J Wilkes; Laura K Becker; Shasank Chennupati; Pamela E Morin; Lena E Winestone; Henry J Henk; Gary H Lyman
Journal:  Leuk Lymphoma       Date:  2020-12-07

5.  Uveal melanoma: Long-term survival.

Authors:  Tomas Radivoyevitch; Emily C Zabor; Arun D Singh
Journal:  PLoS One       Date:  2021-05-18       Impact factor: 3.240

6.  Identification of Key Histone Modifications and Their Regulatory Regions on Gene Expression Level Changes in Chronic Myelogenous Leukemia.

Authors:  Lu-Qiang Zhang; Guo-Liang Fan; Jun-Jie Liu; Li Liu; Qian-Zhong Li; Hao Lin
Journal:  Front Cell Dev Biol       Date:  2021-01-12

Review 7.  Application of precision medicine in clinical routine in haematology-Challenges and opportunities.

Authors:  Tove Wästerlid; Lucia Cavelier; Claudia Haferlach; Marina Konopleva; Stefan Fröhling; Päivi Östling; Lars Bullinger; Thoas Fioretos; Karin E Smedby
Journal:  J Intern Med       Date:  2022-06-04       Impact factor: 13.068

8.  Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached.

Authors:  Massimo Breccia
Journal:  EClinicalMedicine       Date:  2020-02-18

Review 9.  Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.

Authors:  Michele Baccarani; Francesca Bonifazi; Simona Soverini; Fausto Castagnetti; Gabriele Gugliotta; Wael Saber; Noel Estrada-Merly; Gianantonio Rosti; Robert Peter Gale
Journal:  Leukemia       Date:  2022-03-25       Impact factor: 12.883
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.